Novartis in 1999. Following the historic merger of Sandoz and Ciba, the giant Swiss firm struggled to turn its vision of a life sciences company into a commercial success. As top managers left, its share price suffered. Now Vasella is pushing it back along a familar track, seeking new blockbuster drugs, while making visionary investments in biotech companies as a means, of capturing more new ...
|Year of publication:||
Euromoney. - London : Euromoney Publ, ISSN 0014-2433, ZDB-ID 1902325. - 2000, p. 44-61